A randomized, open-label, single dose, 3-period, 3-sequence crossover study to compare the pharmacokinetics and safety/tolerability of "BS-105 enteric-coated tablet A" or "BS-105 enteric-coated tablet B" of Bio-Synectics to original drug in healthy male subjects (Pilot study)
Latest Information Update: 26 Dec 2019
At a glance
- Drugs BS 105 (Primary) ; Posaconazole
- Indications Aspergillosis
- Focus Pharmacokinetics
- Sponsors Bio-Synectics
Most Recent Events
- 16 Dec 2019 Status changed from not yet recruiting to completed.
- 24 Sep 2019 New trial record